Immune Simulator for in silico research relevant to immune-based oncology drug targets

Project: Research project

Project Details

Description

Immune Simulator for in silico research relevant to immune-based oncology drug targets Immune Simulator for in silico research relevant to immune-based oncology drug targets Term of Project. The Project shall commence on the Effective Date of the Agreement and continues in full force and effect until the earlier of (a) acceptable completion of the Project, or (b) termination in accordance with the terms of the Agreement. 2. Description of Project. Immuno-Oncology or IO, a potentially promising new approach to the treatment and management of cancer, is a prioritized area of research for BMS. The dynamic complexity of tumor-human host interactions makes development of optimal immune-based cancer therapy challenging. BMS seeks to develop a computational tool to model tumor-host interactions and their modulation based upon application of therapeutic targets. Such a complex adaptive systems model or immune simulator tool will be used for in silico research as it applies to therapeutic targets (and combinations) that are of interest to BMS. The objective of this model creation is to complement and inform pre-clinical in vivo and ex vivo experimental design with an ultimate goal of reducing the need for such experiments through iterative model refinement. BMS wishes to engage Dr. Ken Buetow and his research staff which may include students or postdoctoral fellows at Arizona State Universitys Complex Adaptive Systems Initiative to develop an immune simulator computational biology model for in silico research relevant to immune-based oncology drug targets in collaboration with BMS scientists. Details of the engagement include: Dr. Buetow will lead the overall project from a complex adaptive systems and theoretical model development perspective. Dr. Buetow and his designated staff agree to work collaboratively with BMS Translational Research and Discovery Medicine and US Medical Oncology colleagues in identifying and aligning on appropriate model scope, data inputs, model output and deliverables, and timelines. Travel to BMS offices or labs in the greater Princeton, NJ area or elsewhere as necessary. Teleconferences and/or webex meetings as necessary. Dr. Buetow/ASU may, with BMS prior, written consent (which may be provided through this Attachment A), sub-contract relevant work or engage other experts in computational or simulation model development, immunology, computer science, or other disciplines who may also work directly with BMS scientists to develop the model. Work will be phased, with an initial phase of pilot model development to test a specific research question and answer simulation (Go/No-Go decision phase for further model development). Initial phase will involve extensive literature review and synthesis for model inputs as well as BMS proprietary/confidential data synthesis. With pilot model success (i.e. ability to replicate or predict experimental data), the project scope will be expanded as outlined in an amendment to Attachment A.
StatusFinished
Effective start/end date12/3/1312/2/16

Funding

  • INDUSTRY: Domestic Company: $2,263,345.00

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.